Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
Total Valuation
ImmunityBio has a market cap or net worth of $1.80B. The enterprise value is €2.93B.
Market Cap$1.80B
Enterprise Value€2.93B
Share Statistics
ImmunityBio has 984,965,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding984,965,150
Owned by Insiders69.21%
Owned by Institutions0.60%
Financial Efficiency
ImmunityBio’s return on equity (ROE) is 0.85 and return on invested capital (ROIC) is -102.24%.
Return on Equity (ROE)0.85
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)-102.24%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee21.97K
Profits Per Employee-616.46K
Employee Count671
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmunityBio is ―. ImmunityBio’s PEG ratio is 0.09.
PE Ratio―
PS Ratio121.07
PB Ratio-3.66
Price to Fair Value-3.66
Price to FCF-4.48
Price to Operating Cash Flow-6.31
PEG Ratio0.09
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
Revenue14.74M
Gross Profit14.74M
Operating Income-344.18M
Pretax Income-413.64M
Net Income-413.56M
EBITDA-264.43M
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -319.70M and capital expenditures -4.31M, giving a free cash flow of -324.01M billion.
Operating Cash Flow-319.70M
Free Cash Flow-324.01M
Free Cash Flow per Share-0.33
Dividends & Yields
ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change-63.90%
50-Day Moving Average2.11
200-Day Moving Average2.39
Relative Strength Index (RSI)35.26
Average Volume (3m)1.07K
Important Dates
ImmunityBio upcoming earnings date is Mar 3, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
ImmunityBio as a current ratio of 3.36, with Debt / Equity ratio of -7.92%
Current Ratio3.36
Quick Ratio3.21
Debt to Market Cap0.42
Net Debt to EBITDA-2.67
Interest Coverage Ratio-2.23
Taxes
In the past 12 months, ImmunityBio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
ImmunityBio EV to EBITDA ratio is -10.06, with an EV/FCF ratio of -6.11.
EV to Sales164.90
EV to EBITDA-10.06
EV to Free Cash Flow-6.11
EV to Operating Cash Flow-6.21
Balance Sheet
ImmunityBio has $153.66M in cash and marketable securities with $0.00 in debt, giving a net cash position of $153.66M billion.
Cash & Marketable Securities$153.66M
Total Debt$0.00
Net Cash$153.66M
Net Cash Per Share$0.16
Tangible Book Value Per Share-$0.72
Margins
Gross margin is 99.55%, with operating margin of -2334.23%, and net profit margin of -2804.77%.
Gross Margin99.55%
Operating Margin-2334.23%
Pretax Margin-2804.77%
Net Profit Margin-2804.77%
EBITDA Margin-1639.63%
EBIT Margin-1758.68%
Analyst Forecast
The average price target for ImmunityBio is $6.07, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.07
Price Target Upside233.67% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―